Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
Publication Date Feb 2015
Publisher CurrentPartnering
Product Type Report
Pages 2477
Single User License help $ 3495.00
Site User License help $ 5245.00
Corporate User License help $ 17495.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

The Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the distribution partnering agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understand and analysis of how and why companies enter distribution deals.
The majority of deals are multicomponent whereby the licensor offers a right to distribute the resultant product of the research collaboration. There are also numerous pure distribution deals whereby the products originator takes on a distribution partner in order to maximize a products presence in the marketplace.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of distribution dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in distribution as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of distribution deals. The chapter includes numerous case studies to enable understanding of both pure distribution deals and multicomponent deals where distribution forms a part.

Chapter 4 provides a review of the leading distribution deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech, most active bigpharma and bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of distribution deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of distribution deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of distribution deals organized by company A-Z, therapy, technology and industry type signed and announced since 2009 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the distribution deal.

In addition the report includes a comprehensive listing of all distribution deals announced since 2009.
Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances.

Report scope

Distribution Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the distribution trends and structure of deals entered into by leading biopharma companies worldwide.

Distribution Partnering Terms and Agreements includes:

Trends in distribution dealmaking in the biopharma industry since 2009
Analysis of distribution deal structure
Case studies of real-life distribution deals
Access to over 2,500 distribution deals documents
The leading distribution deals by value since 2009
Most active distribution dealmakers since 2009
The leading distribution partnering resources


In Distribution Partnering Terms and Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Therapeutic area
Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
The Distribution Partnering Terms and Agreements report provides comprehensive access to available records for over 2,500 distribution deals, including contract documents where available. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in distribution dealmaking

2.1. Introduction
2.2. Definition of distribution deals
2.3. Trends in distribution deals since 2009
2.3.1. Attributes of pure distribution deals
2.3.2. Attributes of distribution in multi-component deals
2.4 . Aligning partners to make the distribution agreement work

Chapter 3 – Overview of distribution deal structure

3.1. Introduction
3.2.Distribution agreement structure
3.3. Example distribution agreements
3.3.1. Case study 1: Zeltiq Aesthetics – Advance Medical – 18 March 2011
3.3.2. Case study 2: QLT – ASD Speciality Healthcare – January 2010
3.4 Distribution rights as part of a wider alliance agreement
3.4.1. Case study 1: Caleco Pharma – Natac Biotech – March 2010
3.4.2. Case study 2: Purdue Pharma – Transcept Pharmaceuticals – July 2009

Chapter 4 – Leading distribution deals

4.1. Introduction
4.2. Top distribution deals by value
4.3. Most active distribution dealmakers
4.4. Big pharma distribution deal activity
4.5. Big biotech distribution deal activity

Chapter 5 – Big pharma distribution deals

5.1. Introduction
5.2. How to use distribution deals
5.3. Big pharma distribution partnering company profiles

Chapter 6 – Big biotech distribution deals

6.1. Introduction
6.2. How to use big biotech partnering deals
6.3. Big biotech distribution partnering company profiles


Chapter 7 – Distribution deals including contracts directory

7.1. Introduction
7.2. Distribution deals with contracts by company A-Z
7.3. Distribution deals with contracts by therapeutic target
7.4 Distribution deals with contracts by technology type
7.5. Distribution deals with contracts by industry sector target

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form – Upgrades to subscription access products
Order Form – Reports

See accompanying volume for the following appendices

Appendix 1 – Distribution dealmaking companies A-Z
Appendix 2 – By stage of development
Appendix 3 – By therapeutic target
Appendix 4 – By technology type
Appendix 5 – Distribution dealmaking references
Appendix 6 – Resources
Appendix 7 – Deal type definitions
Appendix 8 – Resources

TABLE OF FIGURES

Figure 1: Definition of distribution
Figure 2: Trends in distribution deal announcements, 2009-2014
Figure 3: Distribution deals signed at each phase of development, 2009-2014
Figure 4: Issues in implementing distribution agreements
Figure 5: Distribution agreements – what should a contract include?
Figure 6: Components of the distribution deal structure
Figure 7: Top distribution deals by value since 2009
Figure 8: Most active distribution dealmakers 2009-2014
Figure 9: Big pharma – top 50 – distribution deals 2009 to 2014
Figure 10: Big pharma distribution deal frequency - 2009 to 2014
Figure 11: Big biotech – distribution deals 2009 to 2014
Figure 12: Big biotech distribution deal frequency - 2009 to 2014

Title Date Price
2013 Deep Research Report on China Human Use Rabies Vaccine Industry
By QYResearch
2013 Deep Research Report on China Human Use Rabie Vaccine Industry is a professional and depth research report on China Human Use Rabies Vaccine industry. This report has firstly introduced Human Use ...Read More
Jan 2013 $2000.00
Abdominal Obesity-Pipeline Insights, 2014
By Delveinsight
SUMMARYDelveInsight’s,“ Abdominal Obesity-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establ ...Read More
$1250.00
Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed ...Read More
$2000.00
Abortion-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed ...Read More
$2000.00
Abscess-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Abscess-Pipeline Insights, 2014
By Delveinsight
SUMMARYDelveInsight’s,“ Abscess-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the un ...Read More
$1250.00
Absence Seizure- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Absence Seizure- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and m ...Read More
$2000.00
Absence Seizure-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Acid Indigestion / Heartburn/ Pyrosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Acid Indigestion / Heartburn/ Pyrosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase II ...Read More
$2000.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z